Qian Lin
Leina Ma
Shudi Luo
Xiaoming Jiang
Jing Fang
Zhimin Lu
a Cancer Institute of The Affiliated Hospital of Qingdao University and Qingdao Cancer Institute, Qingdao 266061, China;
b Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou 310029, China;
c Zhejiang University Cancer Center, Hangzhou 310029, China
Funds: 82073061, J.F.
This study was supported by grants from the Ministry of Science and Technology of the People's Republic of China (2020YFA0803300 to Z.L., J.F.), the National Natural Science Foundation of China (82030074, Z.L.
81672926, L.M.), the Zhejiang Natural Science Foundation-Key Project (LD21H160003, Z.L.), the Zhejiang University Research Fund (188020*194221901/029, Z.L.), and the Leading Innovative and Entrepreneur Team Introduction Program of Zhejiang (2019R01001, Z.L.). Z.L. is the Kuancheng Wang Distinguished Chair.
Received Date: 2021-04-02
Accepted Date:2021-06-22
Rev Recd Date:2021-06-22
Publish Date:2021-07-20
Abstract
Abstract
Fructose metabolism and fructose kinase KHK–C/A are key factors in the development of lipid oversynthesis-promoted metabolic disorders and cancer. Here, we summarize and discuss the current knowledge about the specific features of fructose metabolism and the distinct roles of KHK–C and KHK–A in metabolic liver diseases and their relevant metabolic disorders and cancer, and we highlight the specific protein kinase activity of KHK–A in tumor development. In addition, different approaches that have been used to inhibit KHK and the exploration of KHK inhibitors in clinical treatment are introduced.Keywords: Fructose,
Glucose,
KHK–C,
KHK-A,
Cancer,
NAFLD,
NASH,
Metabolic disorders
PDF全文下载地址:
http://www.jgenetgenomics.org/article/exportPdf?id=02435ce7-c405-407d-8abe-c0f189817e76&language=en
